Scancell Holdings plc (LON:SCLP - Get Free Report)'s share price was up 4.5% during trading on Tuesday . The stock traded as high as GBX 12.20 ($0.16) and last traded at GBX 12.02 ($0.15). Approximately 1,814,874 shares changed hands during trading, an increase of 150% from the average daily volume of 725,485 shares. The stock had previously closed at GBX 11.50 ($0.15).
Scancell Stock Performance
The stock has a market cap of £108.76 million, a P/E ratio of -1,170.00 and a beta of 0.35. The stock has a fifty day simple moving average of GBX 13.72 and a 200-day simple moving average of GBX 13.63. The company has a debt-to-equity ratio of 61.41, a quick ratio of 13.01 and a current ratio of 3.42.
About Scancell
(
Get Free Report)
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
Featured Articles
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.